Advances such as triple agonists, gene editing, and microbiome therapy offer hope for metabolic diseases, but global access and early detection remain limited.

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN ...

ADHD diagnosis currently relies on behavioral tests and patient interviews – could biomarkers offer a more accurate and ...